103eP From undertesting to undertreatment: Barriers to immunotherapy access in recurrent endometrial cancer in Chile (2010–2024)

Disease recurrence remains common in advanced endometrial cancer (EC) and it is the primary mortality driver. The emergence of checkpoint inhibitor (ICI) therapy has changed the treatment paradigm in recurrent and advanced disease. Whether these advances have translated into clinical practice in Chile is unknown. This study describes treatment patterns, recurrence rates, and post-recurrence management in a EC cohort at a Chilean academic centre.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108129
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

103eP From undertesting to undertreatment: Barriers to immunotherapy access in recurrent endometrial cancer in Chile (2010–2024)

C. A. Ibañez, C. Beltrán Pavez, M. Correa, F. Moraes et al.
ESMO Open
Endometrial and Cervical Cancer Treatments
article

103eP From undertesting to undertreatment: Barriers to immunotherapy access in recurrent endometrial cancer in Chile (2010–2024)

C. A. Ibañez, C. Beltrán Pavez, M. Correa, F. Moraes, M.L. Bravo, P. Perez, J. Romero, M. Caputo
article en

Abstract

Disease recurrence remains common in advanced endometrial cancer (EC) and it is the primary mortality driver. The emergence of checkpoint inhibitor (ICI) therapy has changed the treatment paradigm in recurrent and advanced disease. Whether these advances have translated into clinical practice in Chile is unknown. This study describes treatment patterns, recurrence rates, and post-recurrence management in a EC cohort at a Chilean academic centre.

ESMO OpenVol. 11
Pontificia Universidad Católica de Chile (CL), Clínica Alemana (CL), Fraunhofer Chile Research Foundation (CL), Clínica Las Condes (CL), Colegio Médico de Chile (CL), Instituto Nacional del Cáncer (CL)
Good health and well-being
Openalex Percentile: Top 5%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

103eP From undertesting to undertreatment: Barriers to immunotherapy access in recurrent endometrial cancer in Chile (2010–2024) — C. A. Ibañez, C. Beltrán Pavez, et al. · ESMO Open (2026) | TGRS Research Map | TGRS